Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | KIT | P10721 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | STS | P08842 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 1/20 | 0.37 |
| ▸ | JAK1 | P23458 | 1/20 | 0.37 |
| ▸ | TYK2 | P29597 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 1/20 | 0.37 |
| ▸ | F12 | P00748 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.37 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27053264 | 0.92 | LMNA (0.44) | ESR2MEN1KMT2AF12MAPT | |
| SCHEMBL30552452 | 0.92 | LMNA (0.44) | ESR2MEN1KMT2AF12MAPT | |
| SCHEMBL23580642 | 0.84 | ESR2 (0.42) | ESR2MEN1KMT2AF12NR1H2 | |
| SCHEMBL23580395 | 0.84 | ESR2 (0.42) | ESR2MEN1KMT2AF12NR1H2 | |
| SCHEMBL25846333 | 0.83 | BAZ2B (0.42) | ESR2KITPOLBSTSMEN1 | |
| SCHEMBL30339675 | 0.83 | BAZ2B (0.42) | ESR2KITPOLBSTSMEN1 | |
| SCHEMBL31424863 | 0.81 | SMARCA2 (0.56) | ESR2KITF12 | |
| SCHEMBL6483420 | 0.78 | BAZ2B (0.45) | ESR2MEN1KMT2AKDM4EMAPT | |
| SCHEMBL31424878 | 0.77 | SMARCA2 (0.43) | KITF12MKNK1 | |
| SCHEMBL24102111 | 0.76 | MKNK1 (0.41) | ESR2KITJAK1F12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250074916-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | PRELUDE THERAPEUTICS INCORPORATED | 2025-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074916-A1 | BRM TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE | ABCG2, BRIX1, MRPS28 | ESR2 942/4885KIT 658/4885POLB 1396/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.